Name: 글로벌 시장 동향
SKU: CD2247
Availability: InStock

보고서 요약(국문)

개요
전 세계 전립선암 진단 시장은 2022년 51억 달러 규모에 달했으며, 2023년부터 2030년까지 연평균 11.1%의 성장률을 보이며 2030년에는 116억 달러에 이를 것으로 예상됩니다.
전립선암은 남성의 혈액에서 전립선 특이 항원(PSA) 수치를 검사하거나 직장수지검사(DRE)를 통해 조기에 발견할 수 있습니다. 미국에서 실시된 한 연구에 따르면, PSA 및 DRE를 이용한 연례 검진은 검진을 받지 않은 남성보다 더 많은 전립선암을 발견했지만, 사망률을 낮추지는 못했습니다.
전립선암의 조기 진단은 매우 중요합니다. 일단 병기가 결정되면, 어떤 치료법을 사용하더라도 효과가 떨어지기 때문입니다. 전립선암은 전립선 조직을 채취하여 암세포 유무를 검사하는 전립선 생검을 통해서도 진단됩니다. 일부 비뇨기과 의사는 보다 명확한 생검 부위를 확보하기 위해 MRI 및 초음파 기술을 사용합니다. PSA 혈액 검사는 주로 증상이 없는 남성의 전립선암 선별 검사에 사용됩니다. 또한 전립선암이 의심되는 남성에게 시행하는 첫 번째 검사 중 하나이기도 합니다.
더 나아가 자기공명영상(MRI)에 인공지능(AI)이 통합되고, 진단 개선을 위한 새로운 기술이 증가하고, 남성들의 조기 진단에 대한 인식이 높아지고 있는 것이 향후 시장 성장을 견인할 요인입니다.
시장 동향
성장하는 파이프라인 제품
최근 남성 전립선암 발병률 증가로 전립선암 진단 수요가 늘어나면서 여러 파이프라인 제품이 성장세를 보이고 있습니다. 예를 들어, 란테우스(Lantheus)는 2023년에 PSMA에 결합하는 Tc-99m 표지 분자인 1404를 개발하고 있습니다. 1404는 국소 전립선암뿐만 아니라 연조직 및 뼈 전이를 진단하고 검출하는 SPECT/CT 영상화제로 사용됩니다. 로톱(ROTOP)은 유럽에서 1404의 개발, 제조 및 상용화에 대한 독점권을 보유하고 있습니다.

예를 들어, 세인트 빈센트 병원은 클래리티 파마슈티컬스(Clarity Pharmaceuticals Ltd)와 협력하여 PSMA 음성 전립선암에서 구리-64 SAR 봄베신(Copper-64 SAR Bombesin)을 평가하기 위한 2상 임상 시험을 진행했습니다. 이 시험은 PSA 수치가 상승하고 PSMA PET 검사에서 음성인 남성에서 방사성 동위원소로 표지된 봄베신 길항제 유사체인 64Cu-SAR-BBN PET의 진단 가능성을 탐색하기 위한 것입니다. 예상 완료일은 2024년 6월입니다.
인공지능 통합을 통한 진단 개선
인공지능(AI)을 활용한 전립선암 진단 연구 또한 빠르게 발전하고 있으며, 현재 표준 진단 경로의 모든 측면을 개선할 잠재력을 가지고 있습니다. 더욱이, AI 모델은 전립선 분할, MRI-초음파 영상 정합, MRI-초음파 융합 생검, MRI-조직병리학 정합과 같이 노동 집약적이고 경험에 의존적인 암 진단 보조 작업을 줄여 암 진단을 지원할 수 있습니다.

예를 들어, 2023년 3월 Qritive는 첨단 인공지능(AI) 기반 전립선암 진단 도구인 QAi Prostate를 출시했습니다. QAi Prostate는 고급 머신러닝(ML) 알고리즘을 활용하여 전립선 선암 부위를 정확하게 식별하고 생검 조직 샘플에서 악성 및 양성 종양 부위를 분류할 수 있습니다.
생검 시술 관련 합병증
경직장 초음파 유도 생검(TRUS biopsy)은 통증, 급성 요폐, 혈뇨, 혈정액증, 직장 출혈, 발기부전, 감염 및 패혈증을 포함한 몇 가지 위험과 관련이 있습니다. 전 세계적으로 질병 및 패혈증 발생률이 증가하고 있는 것은 우려스러운 부분입니다. 과거에는 TRUS 생검을 받은 환자의 약 1%에서 감염 합병증이 발생했지만, 최근 몇 년 동안 이 수치는 2~4%로 증가했습니다. 면역결핍, 제2형 당뇨병, 최근 입원력, 만성 폐쇄성 폐질환(COPD) 등 패혈증 위험 요인이 있는 남성은 경직장 초음파 유도 생검(TRUS biopsy) 외의 다른 시술을 고려할 수 있습니다.
세그먼트 분석
전 세계 전립선암 진단 시장은 검사 유형, 암 유형, 병기, 최종 사용자 및 지역별로 세분화됩니다.
이 부문은 시장 점유율의 약 45.3%를 차지했습니다.
전립선 특이 항원(PSA)은 전립선 세포에서 생성되는 단백질이며, PSA 검사는 남성의 전립선암(PCa) 진단 및 치료 후 재발 여부 확인을 위한 추적 관찰에 사용됩니다. PSA 검사는 남성의 혈액 내 PSA 수치를 측정하여 전립선암을 조기에 발견하는 데 필수적입니다.
메디케어와 여러 민간 보험사는 50세 이상 메디케어 수혜 남성에게 매년 PSA 검사를 보장합니다. 전립선암 발병률 증가로 인해 PSA 검사가 임상의와 병원 사이에서 인기를 얻고 있습니다. 예를 들어, 혁신적인 진단 솔루션 개발업체인 LynxDx는 2023년 2월, 비침습적이고 데이터 기반의 소변 전립선암 선별 검사인 MyProstateScore 2.0(MPS2)을 출시했습니다. MPS2는 전립선 특이 항원(PSA) 수치가 높거나 직장수지검사(DRE)에서 이상 소견이 나타난 환자에게 매우 정확하고 계층화된 위험 평가 정보를 제공하여 임상적 의사결정을 지원합니다. PSA 검사의 혁신과 발전이 지속됨에 따라 향후 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
지역별 분석
북미는 2022년 시장 점유율의 약 39.2%를 차지했습니다.
북미는 전 세계 전립선암 진단 시장을 주도하고 있으며, 미국이 가장 큰 비중을 차지하고 있습니다. 전립선암은 미국 남성에게 가장 흔한 암 중 하나이며, 관련 통계에서도 이를 확인할 수 있습니다. 피부암 다음으로 미국 남성 8명 중 1명꼴로 발생하는 전립선암은 미국 남성에게 가장 흔한 암입니다.
미국 암 협회는 2022년에 약 268,490건의 새로운 전립선암 사례가 발견되었다고 추산했습니다. 전립선암 중에는 공격적인 유형도 있지만 대부분은 천천히 자랍니다. 사망자 수는 매년 증가하고 있으며, 전립선암은 미국 남성 암 사망 원인 2위입니다. 따라서 조기 진단이 매우 중요합니다.
COVID-19 영향 분석
코로나19 팬데믹은 임상 시험 전반에 걸쳐 행정 및 임상 활동에 영향을 미쳤습니다. 감염 통제 조치가 시행되면서 팬데믹 초기에는 임상 시험 시작 및 참가자 모집이 중단되는 경우가 많았습니다. 2021년 3월 보고서에 따르면 팬데믹 기간 동안 새로운 종양학 임상 시험이 60% 감소한 것으로 나타나 새로운 암 치료법 개발이 둔화될 것이라는 우려가 커졌습니다.
팬데믹 기간 동안 연구 개발 노력의 초점이 바뀌었고, 특히 COVID-19 백신 및 치료제 개발에 많은 노력이 집중되었습니다. 영국의 주요 암 연구 자선 단체인 Cancer Research UK는 암 환자를 보호하고 임상 연구 인력을 코로나19 최전선 의료 서비스 지원에 재배치하기 위해 임상 시험의 95%에 대한 모집을 중단했습니다.
검사 유형별
• 직장수지검사
• PSA 혈액검사
• 생검
o 전립선 생검
o 경직장 생검
o 경회음 생검
o 림프절 생검
• 유전자 검사
• 영상 검사
o 경직장 초음파(TRUS)
o 자기공명영상(MRI)
o 핵의학 영상
• 기타
암 유형별
• 양성 전립선 비대증
• 전립선 선암
• 소세포암
• 도관 전립선암
• 기타
병기별
• 1기
• 2기
• 3기
• 4기
최종 사용자별
• 암 센터
• 전문 클리닉
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양 지역
• 중동 및 아프리카
주요 개발 사항
• 2023년 7월, BPGbio는 Grupo Terralpe와 협력하여 멕시코에서 AI 기반 전립선암 진단 검사를 제공하기 시작했습니다. 전략적 파트너십을 통해 Grupo Terralpe는 BPGbio의 혁신적인 전립선암 검사인 pstateDx를 멕시코에 도입하여 PSA 수치가 높아 전립선암 가능성이 있는 환자의 임상적 의사결정을 지원할 예정입니다.

• 2023년 2월, 혁신적인 진단 솔루션 개발업체인 LynxDx는 비침습적이고 데이터 기반의 소변 전립선암 선별 검사인 MyProstateScore 2.0(MPS2)을 출시했습니다. MPS2는 전립선 특이 항원(PSA) 수치가 높거나 직장수지검사(DRE)에서 이상 소견이 나타난 환자에게 매우 정확하고 계층화된 위험 평가 정보를 제공하여 임상적 의사결정을 지원합니다.

• 2023년 3월, 노바티스의 플루빅토(Pluvicto)는 진행성 PSMA 양성 전이성 거세 저항성 전립선암 치료를 위한 최초의 표적 방사성 리간드 치료제로 FDA 승인을 받았습니다.
경쟁 환경
전 세계 전립선암 진단 시장의 주요 업체로는 Myriad Genetics, Inc., Quanterix Corporation, MDx Health, Siemens Healthineers, F. Hoffman-La Roche AG, OPKO Health, Inc., Thermo Fisher Scientific Inc., Cellanyx Diagnostics Inc., MiR Scientific, Proteomedix 등이 있습니다.
보고서 구매 이유

• 검사 유형, 암 유형, 병기, 최종 사용자 및 지역별 전 세계 전립선암 진단 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악하기 위해

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별하기 위해

• 모든 세그먼트를 포함한 전립선암 진단 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트

보고서 구매 이유 • PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 Excel 파일로 제공됩니다.
글로벌 전립선암 진단 시장 보고서는 약 53개의 표, 54개의 그림, 그리고 195페이지 분량으로 구성됩니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Prostate Cancer Diagnostics Market reached US$ 5.1 billion in 2022 and is expected to reach US$ 11.6 billion by 2030 growing with a CAGR of 11.1% during the forecast period 2023-2030.
Prostate cancer can often be found early by testing prostate-specific antigen (PSA) levels in a man’s blood or digital rectal exam (DRE). According to a study in the United States, the annual screening with PSA and DRE did detect more prostate cancers than in men not screened, but this screening did not lower the prostate cancer death rate.
Early diagnosis of prostate cancer effectively is crucial. Once the staging begins, treating with any available procedure becomes challenging. It is also diagnosed with a prostate biopsy, which removes tissue from the prostate to examine it for cancer cells. Some urologists use MRI and ultrasound technology to achieve a more apparent biopsy target. The PSA blood test is used mainly to screen for prostate cancer in men without symptoms. It’s also one of the first tests done in men suspecting prostate cancer.
Furthermore, the integration of AI in magnetic resonance imaging (MRI), increasing new technologies for improving diagnosis, and rising awareness about early diagnosis among males are the factors that will drive the market in the forthcoming years.
Dynamics
Rising Pipeline products
Several Pipeline products are on the rise as the demand for prostate cancer diagnosis increased in recent years due to the rising incidence of prostate cancer among males. For instance, in 2023, Lantheus is working on the development of 1404, which is a Tc-99m-labeled molecule that binds to PSMA and is used as a SPECT/CT imaging agent to diagnose and detect localized prostate cancer as well as soft tissue and bone metastases. ROTOP has exclusive rights to develop, manufacture, and commercialize 1404 in Europe.
For instance, St Vincent's Hospital collaborated with Clarity Pharmaceuticals Ltd to conduct phase 2 clinical trials to evaluate Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer. Radiolabeled antagonist analog of bombesin to explore the diagnostic potential of 64Cu-SAR-BBN PET In men with rising PSA and negative PSMA PET. The estimated completion date is June 2024.
Improvements in Diagnosis with the Integration of Artificial Intelligence
Research on AI-assisted prostate cancer diagnosis is also evolving rapidly and has the potential to facilitate all aspects of the current standard diagnostic pathway. Moreover, AI models can help cancer diagnosis by reducing supporting tasks in cancer detection that are labor and experience-intensive, such as prostate gland segmentation, MRI-ultrasound registration, MRI-ultrasound fusion biopsies, and MRI-histopathology registration for developing cancer detection models.
For instance, in March 2023, Qritive introduced QAi Prostate, an advanced artificial intelligence (AI)-powered prostate cancer diagnosis tool. By leveraging advanced machine learning (ML) algorithms, QAi Prostate can accurately identify prostatic adenocarcinoma regions and classify malignant and benign tumor areas in biopsy tissue samples.
Complications related to Biopsy procedures
TRUS biopsy is associated with some risks, including pain, acute urinary retention, haematuria, haematospermia, rectal bleeding, erectile dysfunction, infection, and sepsis. The rising rates of disease and sepsis internationally are of concern. Historically, infection complicated approximately 1% of patients who underwent TRUS biopsy, but this figure has risen to 2–4% in recent years. Men with significant risk factors for sepsis, such as immunocompromise, type 2 diabetes mellitus, recent hospitalization, and COPD (Chronic obstructive pulmonary disease), could be considered for procedures other than TRUS biopsy.
Segment Analysis
The global prostate cancer diagnostics is segmented based on test type, cancer type, stage, end-user, and region.
The Segment Accounted for Approximately 45.3% of the Market Share
Prostate-specific Antigen (PSA) is a protein produced by prostate cells, and the PSA test is performed to diagnose prostate cancer (PCa) in men and for follow-up post-treatment to check if the cancer relapses. PSA testing is essential for detecting prostate cancer, which measures PSA levels in a man’s blood.
Medicare and several private insurers provide coverage for an annual PSA test for all Medicare-eligible men aged 50 and older. PSA testing is gaining popularity among clinicians and hospitals owing to the increasing number of people affected by prostate cancer. For instance, on February 2023, LynxDx, Inc., a developer of innovative diagnostic solutions, is introducing MyProstateScore 2.0 (MPS2), a non-invasive, data-driven, urine prostate cancer screening test that provides highly accurate, stratified risk assessment insights to guide clinical decisions for patients with elevated prostate-specific antigen (PSA) or abnormal digital rectal exam (DRE) findings. Due to increased innovations and advancements in PSA testing is expected to hold the largest market share in the forthcoming period.
Geographical Analysis
North America accounted for Approximately 39.2% of the Market Share in 2022
North America dominates the global prostate cancer diagnostics market, with the United States accounting as the primary contributor. Prostate cancer is one of the most common cancers in American men, which is made apparent by the statistics surrounding it. It affects 1 out of eight men in the U.S. after skin cancer; it is the most common cancer in U.S. men.
American Cancer Society estimated that in 2022, around 268,490 novel cases of prostate cancer were detected. Some of prostate cancers are aggressive, but most of them grow slowly. The number of deaths increases yearly, making prostate cancer the second leading cause of cancer death in men in the United States. Hence, it is considered to have an early diagnosis of the condition.
COVID-19 Impact Analysis
The effects of the pandemic on clinical trials were felt throughout administrative and clinical practices. Clinical trial initiation and recruitment were typically halted at the beginning of the pandemic as infection control measures were implemented. In a March 2021 report, a 60% decrease in new oncology clinical trials during the pandemic was noted, fueling concerns regarding slowing the development of new cancer therapies.
The focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. A major UK-based cancer research charity, Cancer Research UK, halted recruitment in 95% of their clinical trials, both to protect cancer patients and to cope with the redeployment of clinical research staff to support frontline COVID-19-facing healthcare services.
By Test Type
• Digital Rectal Exam
• PSA Blood Test
• Biopsy
o Prostate Biopsy
o Transrectal Biopsy
o Transperineal Biopsy
o Lymph node Biopsy
• Genetic Testing
• Imaging Tests
o Transrectal Ultrasound (TRUS)
o Magnetic Resonance Imaging (MRI)
o Nuclear Imaging
• Others
By Cancer Type
• Benign Prostate Hyperplasia
• Prostatic Adenocarcinoma
• Small Cell Carcinoma
• Ductal prostate cancer
• Others
By Stage
• I
• II
• III
• IV
By End Users
• Cancer Centers
• Specialty Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In July 2023, BPGb partnered with Grupo Terralpe to Offer AI-Discovered Prostate Cancer Diagnostic Test in Mexico. Through their strategic partnership, Grupo Terralpe will bring the pstateDx test, BPGbio’s novel prostate cancer test to Mexico in an effort to improve clinical decision support for patients with elevated PSA levels who may have prostate cancer.
• On February 2023, LynxDx, Inc., a developer of innovative diagnostic solutions is introducing MyProstateScore 2.0 (MPS2), a non-invasive, data-driven, urine prostate cancer screening test that provides highly accurate, stratified risk assessment insights to guide clinical decisions for patients with elevated prostate-specific antigen (PSA) or abnormal digital rectal exam (DRE) findings.
• On March 2023, Novartis Pluvicto was approved by FDA as the first targeted radioligand therapy for the treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer
Competitive Landscape
The major global players in the prostate cancer diagnostics market include Myriad Genetics, Inc., Quanterix Corporation, MDx Health, Siemens Healthineers, F. Hoffman-La Roche AG, OPKO Health, Inc., Thermo Fisher Scientific Inc., Cellanyx Diagnostics Inc., MiR Scientific, and Proteomedix among others.
Why Purchase the Report?
• To visualize the global prostate cancer diagnostics segmentation based on test type, cancer type, stage, end user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of prostate cancer diagnostics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global prostate cancer diagnostics market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Test Type
3.2. Snippet by Cancer Type
3.3. Snippet by Stage
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Pipeline products
4.1.1.2. Improvements in Diagnosis with the Integration of Artificial Intelligence
4.1.2. Restraints
4.1.2.1. Complications related to Biopsy procedures
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Test Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
7.1.2. Market Attractiveness Index, By Test Type
7.2. Digital Rectal Exam
7.3. PSA Blood Test
7.4. Biopsy
7.4.1.1. Prostate Biopsy
7.4.1.2. Transrectal Biopsy
7.4.1.3. Transperineal Biopsy
7.4.1.4. Lymph node Biopsy
7.5. Genetic Testing
7.6. Imaging Tests
7.6.1.1. Transrectal Ultrasound (TRUS)
7.6.1.2. Magnetic Resonance Imaging (MRI)
7.6.1.3. Nuclear Imaging
7.7. Others
8. By Cancer Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.1.2. Market Attractiveness Index, By Cancer Type
8.2. Benign Prostate Hyperplasia
8.3. Prostatic Adenocarcinoma
8.4. Small Cell Carcinoma
8.5. Ductal prostate cancer
8.6. Others
9. By Stage
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
9.1.2. Market Attractiveness Index, By Stage
9.2. I
9.3. II
9.4. III
9.5. IV
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Cancer Centers
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.6.1. China
11.5.6.2. India
11.5.6.3. Japan
11.5.6.4. Australia
11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Myriad Genetics, Inc.
13.1.1. Company Overview
13.1.2. Product Type Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Quanterix Corporation
13.3. MDx Health
13.4. Siemens Healthineers
13.5. F. Hoffman-La Roche AG
13.6. OPKO Health, Inc
13.7. Thermo Fisher Scientific Inc.
13.8. Cellanyx Diagnostics Inc.
13.9. MiR Scientific LLC
13.10. Proteomedix
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Myriad Genetics, Inc., 4.	Key Developments, Quanterix Corporation, MDx Health, Siemens Healthineers, F. Hoffman-La Roche AG, OPKO Health, Inc, Thermo Fisher Scientific Inc., Cellanyx Diagnostics Inc., MiR Scientific LLC, Proteomedix

표 목록 (Tables)

List of Tables

Table 1 Global Prostate Cancer Diagnostics Market Value, By Test Type, 2023, 2027 & 2031 (US$ Billion)

Table 2 Global Prostate Cancer Diagnostics Market Value, By Cancer Type, 2023, 2027 & 2031 (US$ Billion)

Table 3 Global Prostate Cancer Diagnostics Market Value, By Stage, 2023, 2027 & 2031 (US$ Billion)

Table 4 Global Prostate Cancer Diagnostics Market Value, By End-User, 2023, 2027 & 2031 (US$ Billion)

Table 5 Global Prostate Cancer Diagnostics Market Value, By Region, 2023, 2027 & 2031 (US$ Billion)

Table 6 Global Prostate Cancer Diagnostics Market Value, By Test Type, 2023, 2027 & 2031 (US$ Billion)

Table 7 Global Prostate Cancer Diagnostics Market Value, By Test Type, 2022-2031 (US$ Billion)

Table 8 Global Prostate Cancer Diagnostics Market Value, By Cancer Type, 2023, 2027 & 2031 (US$ Billion)

Table 9 Global Prostate Cancer Diagnostics Market Value, By Cancer Type, 2022-2031 (US$ Billion)

Table 10 Global Prostate Cancer Diagnostics Market Value, By Stage, 2023, 2027 & 2031 (US$ Billion)

Table 11 Global Prostate Cancer Diagnostics Market Value, By Stage, 2022-2031 (US$ Billion)

Table 12 Global Prostate Cancer Diagnostics Market Value, By End-User, 2023, 2027 & 2031 (US$ Billion)

Table 13 Global Prostate Cancer Diagnostics Market Value, By End-User, 2022-2031 (US$ Billion)

Table 14 Global Prostate Cancer Diagnostics Market Value, By Region, 2023, 2027 & 2031 (US$ Billion)

Table 15 Global Prostate Cancer Diagnostics Market Value, By Region, 2022-2031 (US$ Billion)

Table 16 North America Prostate Cancer Diagnostics Market Value, By Test Type, 2022-2031 (US$ Billion)

Table 17 North America Prostate Cancer Diagnostics Market Value, By Cancer Type, 2022-2031 (US$ Billion)

Table 18 North America Prostate Cancer Diagnostics Market Value, By Stage, 2022-2031 (US$ Billion)

Table 19 North America Prostate Cancer Diagnostics Market Value, By End-User, 2022-2031 (US$ Billion)

Table 20 North America Prostate Cancer Diagnostics Market Value, By Country, 2022-2031 (US$ Billion)

Table 21 South America Prostate Cancer Diagnostics Market Value, By Test Type, 2022-2031 (US$ Billion)

Table 22 South America Prostate Cancer Diagnostics Market Value, By Cancer Type, 2022-2031 (US$ Billion)

Table 23 South America Prostate Cancer Diagnostics Market Value, By Stage, 2022-2031 (US$ Billion)

Table 24 South America Prostate Cancer Diagnostics Market Value, By End-User, 2022-2031 (US$ Billion)

Table 25 South America Prostate Cancer Diagnostics Market Value, By Country, 2022-2031 (US$ Billion)

Table 26 Europe Prostate Cancer Diagnostics Market Value, By Test Type, 2022-2031 (US$ Billion)

Table 27 Europe Prostate Cancer Diagnostics Market Value, By Cancer Type, 2022-2031 (US$ Billion)

Table 28 Europe Prostate Cancer Diagnostics Market Value, By Stage, 2022-2031 (US$ Billion)

Table 29 Europe Prostate Cancer Diagnostics Market Value, By End-User, 2022-2031 (US$ Billion)

Table 30 Europe Prostate Cancer Diagnostics Market Value, By Country, 2022-2031 (US$ Billion)

Table 31 Asia-Pacific Prostate Cancer Diagnostics Market Value, By Test Type, 2022-2031 (US$ Billion)

Table 32 Asia-Pacific Prostate Cancer Diagnostics Market Value, By Cancer Type, 2022-2031 (US$ Billion)

Table 33 Asia-Pacific Prostate Cancer Diagnostics Market Value, By Stage, 2022-2031 (US$ Billion)

Table 34 Asia-Pacific Prostate Cancer Diagnostics Market Value, By End-User, 2022-2031 (US$ Billion)

Table 35 Asia-Pacific Prostate Cancer Diagnostics Market Value, By Country, 2022-2031 (US$ Billion)

Table 36 Middle East & Africa Prostate Cancer Diagnostics Market Value, By Test Type, 2022-2031 (US$ Billion)

Table 37 Middle East & Africa Prostate Cancer Diagnostics Market Value, By Cancer Type, 2022-2031 (US$ Billion)

Table 38 Middle East & Africa Prostate Cancer Diagnostics Market Value, By Stage, 2022-2031 (US$ Billion)

Table 39 Middle East & Africa Prostate Cancer Diagnostics Market Value, By End-User, 2022-2031 (US$ Billion)

Table 40 Myriad Genetics, Inc.: Overview

Table 41 Myriad Genetics, Inc.: Product Portfolio

Table 42 Myriad Genetics, Inc.: Key Developments

Table 43 Quanterix Corporation: Overview

Table 44 Quanterix Corporation: Product Portfolio

Table 45 Quanterix Corporation: Key Developments

Table 46 MDx Health: Overview

Table 47 MDx Health: Product Portfolio

Table 48 MDx Health: Key Developments

Table 49 Siemens Healthcare GmbH: Overview

Table 50 Siemens Healthcare GmbH: Product Portfolio

Table 51 Siemens Healthcare GmbH: Key Developments

Table 52 F. Hoffman-La Roche AG: Overview

Table 53 F. Hoffman-La Roche AG: Product Portfolio

Table 54 F. Hoffman-La Roche AG: Key Developments

Table 55 OPKO Health, Inc: Overview

Table 56 OPKO Health, Inc: Product Portfolio

Table 57 OPKO Health, Inc: Key Developments

Table 58 Thermo Fisher Scientific: Overview

Table 59 Thermo Fisher Scientific: Product Portfolio

Table 60 Thermo Fisher Scientific: Key Developments

Table 61 Cellanyx Diagnostics Inc: Overview

Table 62 Cellanyx Diagnostics Inc: Product Portfolio

Table 63 Cellanyx Diagnostics Inc: Key Developments

Table 64 MiR Scientific: Overview

Table 65 MiR Scientific: Product Portfolio

Table 66 MiR Scientific: Key Developments

Table 67 Proteomedix: Overview

Table 68 Proteomedix: Product Portfolio

Table 69 Proteomedix: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 2 Global Prostate Cancer Diagnostics Market Share, By Test Type, 2022 & 2031 (%)

Figure 3 Global Prostate Cancer Diagnostics Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 4 Global Prostate Cancer Diagnostics Market Share, By Stage, 2022 & 2031 (%)

Figure 5 Global Prostate Cancer Diagnostics Market Share, By End-User, 2022 & 2031 (%)

Figure 6 Global Prostate Cancer Diagnostics Market Share, By Region, 2022 & 2031 (%)

Figure 7 Global Prostate Cancer Diagnostics Market Y-o-Y Growth, By Test Type, 2022-2031 (%)

Figure 8 Digital Rectal Exam Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 9 PSA Blood Test Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 10 Biopsy Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 11 Genetic Testing Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 12 Imaging Tests Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 13 Others Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 14 Global Prostate Cancer Diagnostics Market Y-o-Y Growth, By Cancer Type, 2022-2031 (%)

Figure 15 Benign Prostate Hyperplasia Cancer Type in Global Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 16 Prostatic Adenocarcinoma Cancer Type in Global Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 17 Small Cell Carcinoma Cancer Type in Global Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 18 Ductal Prostate Cancer Type in Global Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 19 Others Cancer Type in Global Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 20 Global Prostate Cancer Diagnostics Market Y-o-Y Growth, By Stage, 2022-2031 (%)

Figure 21 I Stage in Global Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 22 II Stage in Global Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 23 III Stage in Global Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 24 IV Stage in Global Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 25 Global Prostate Cancer Diagnostics Market Y-o-Y Growth, By End-User, 2022-2031 (%)

Figure 26 Hospitals in Global Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 27 Diagnostic Centers in Global Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 28 Specialty Clinics in Global Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 29 Others in Global Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 30 Global Prostate Cancer Diagnostics Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 31 North America Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 32 Asia-Pacific Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 33 Europe Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 34 South America Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 35 Middle East and Africa Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 36 North America Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 37 North America Prostate Cancer Diagnostics Market Share, By Test Type, 2022 & 2031 (%)

Figure 38 North America Prostate Cancer Diagnostics Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 39 North America Prostate Cancer Diagnostics Market Share, By Stage, 2022 & 2031 (%)

Figure 40 North America Prostate Cancer Diagnostics Market Share, By End-User, 2022 & 2031 (%)

Figure 41 North America Prostate Cancer Diagnostics Market Share, By Country, 2022 & 2031 (%)

Figure 42 South America Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 43 South America Prostate Cancer Diagnostics Market Share, By Test Type, 2022 & 2031 (%)

Figure 44 South America Prostate Cancer Diagnostics Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 45 South America Prostate Cancer Diagnostics Market Share, By Stage, 2022 & 2031 (%)

Figure 46 South America Prostate Cancer Diagnostics Market Share, By End-User, 2022 & 2031 (%)

Figure 47 South America Prostate Cancer Diagnostics Market Share, By Country, 2022 & 2031 (%)

Figure 48 Europe Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 49 Europe Prostate Cancer Diagnostics Market Share, By Test Type, 2022 & 2031 (%)

Figure 50 Europe Prostate Cancer Diagnostics Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 51 Europe Prostate Cancer Diagnostics Market Share, By Stage, 2022 & 2031 (%)

Figure 52 Europe Prostate Cancer Diagnostics Market Share, By End-User, 2022 & 2031 (%)

Figure 53 Europe Prostate Cancer Diagnostics Market Share, By Country, 2022 & 2031 (%)

Figure 54 Asia-Pacific Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 55 Asia-Pacific Prostate Cancer Diagnostics Market Share, By Test Type, 2022 & 2031 (%)

Figure 56 Asia-Pacific Prostate Cancer Diagnostics Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 57 Asia-Pacific Prostate Cancer Diagnostics Market Share, By Stage, 2022 & 2031 (%)

Figure 58 Asia-Pacific Prostate Cancer Diagnostics Market Share, By End-User, 2022 & 2031 (%)

Figure 59 Asia-Pacific Prostate Cancer Diagnostics Market Share, By Country, 2022 & 2031 (%)

Figure 60 Middle East & Africa Prostate Cancer Diagnostics Market Value, 2022-2031 (US$ Billion)

Figure 61 Middle East & Africa Prostate Cancer Diagnostics Market Share, By Test Type, 2022 & 2031 (%)

Figure 62 Middle East & Africa Prostate Cancer Diagnostics Market Share, By Cancer Type, 2022 & 2031 (%)

Figure 63 Middle East & Africa Prostate Cancer Diagnostics Market Share, By Stage, 2022 & 2031 (%)

Figure 64 Middle East & Africa Prostate Cancer Diagnostics Market Share, By End-User, 2022 & 2031 (%)

Figure 65 Myriad Genetics, Inc.: Financials

Figure 66 Quanterix Corporation: Financials

Figure 67 MDx Health: Financials

Figure 68 Siemens Healthcare GmbH: Financials

Figure 69 F. Hoffman-La Roche AG: Financials

Figure 70 OPKO Health, Inc: Financials

Figure 71 Thermo Fisher Scientific: Financials

Figure 72 Cellanyx Diagnostics Inc: Financials

Figure 73 MiR Scientific: Financials

Figure 74 Proteomedix: Financials

세계 전립선암 진단 시장 – 2023-2030

Global Prostate Cancer Diagnostics Market - 2023-2030